VRTX
Vertex Pharmaceuticals Inc
503.50$
-0.2%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 51.1% | 9.3% | 48.6% | -141.9% | 49.4% | 20.1% | 29.6% | 36.2% | 40.4% | 15.4% | 47.8% | 33.8% | 34.0% | |
| 1.7% | 2.3% | 2.0% | 2.0% | 1.9% | 1.6% | 1.7% | 1.7% | 1.8% | 1.7% | 1.9% | 1.7% | 1.8% | |
| 5.3% | 8.3% | 7.1% | 5.8% | 6.7% | 5.8% | 6.0% | 5.6% | 6.3% | 4.9% | 5.6% | 5.1% | 5.5% | |
| 7.6% | -33.3% | 4.8% | -9.1% | 5.7% | -19.2% | -9.7% | -4.5% | 4.9% | -29.4% | 8.2% | -3.4% | -5.3% | |
| 1.6% | 2.3% | 9.2% | 2.9% | 2.4% | 3.2% | 1.5% | 4.9% | 3.3% | 4.6% | 4.5% | 3.4% | 3.9% | |
| -4.7% | -35.2% | -79.5% | -17.5% | -12.6% | -28.2% | -2.0% | -16.3% | -3.8% | -8.9% | -14.5% | -1.4% | -7.0% | |
| 0.6% | – | – | – | – | – | – | – | – | – | – | – | – | |
| -4.7% | -5.9% | -4.9% | -12.1% | -11.1% | -14.4% | -15.4% | -13.2% | -34.8% | -4.1% | -18.9% | -14.2% | -17.8% | |
| – | – | – | – | -0.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | |
| -6.6% | -4.8% | -13.3% | -13.6% | -14.0% | -13.4% | -24.6% | -11.8% | -37.5% | -2.4% | -18.0% | -12.8% | -17.4% | |
| 38.8% | -29.6% | -44.8% | -173.1% | 23.7% | -23.2% | 4.1% | 10.0% | -1.1% | 4.3% | 14.0% | 19.5% | 9.3% | |
| 49.4% | 7.0% | 39.4% | -144.8% | 47.0% | 16.9% | 28.1% | 31.3% | 37.0% | 10.8% | 43.3% | 30.4% | 30.1% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.